新诊断年轻骨髓瘤患者自体移植对比口服化疗联合来那度胺的汇总分析
中位随访46个月,MEL200-ASCT较CC+R显著改善无进展生存期1、无进展生存期2和总生存期,且获益见于预后良好和不良患者,仅53%的CC+R复发患者首次复发时接受自体移植。
要点
- MEL200-ASCT组中位PFS1为42个月,CC+R组为24个月(HR 0.53,P<0.001)。
- 4年PFS2率MEL200-ASCT组71% vs CC+R组54%(HR 0.53,P<0.001)。
- 4年OS率MEL200-ASCT组84% vs CC+R组70%(HR 0.51,P<0.001)。
核心结论
- 这些数据证实,一线自体移植是所有年轻骨髓瘤患者的标准方法。
研究设计与样本
- 对2项III期试验(RV-MM-209和EMN-441)进行汇总分析。
- 共268例患者随机接受2个疗程马法兰200 mg/m2联合自体移植(MEL200-ASCT),261例随机接受化疗联合来那度胺(CC+R)。
- 中位随访46个月。
主要发现
- MEL200-ASCT组中位PFS1为42个月,CC+R组为24个月(HR 0.53;P<0.001)。
- 4年PFS2率MEL200-ASCT组为71%,CC+R组为54%(HR 0.53,P<0.001)。
- 4年OS率MEL200-ASCT组为84%,CC+R组为70%(HR 0.51,P<0.001)。
- 预后良好和预后不良患者中均观察到MEL200-ASCT的获益。
- CC+R组复发患者中仅53%在首次复发时接受自体移植。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In newly diagnosed myeloma patients, upfront autologous transplant (ASCT) prolongs progression-free survival 1 (PFS1) compared with chemotherapy plus lenalidomide (CC+R). Salvage ASCT at first relapse may still effectively rescue patients who did not receive upfront ASCT. To evaluate the long-term benefit of upfront ASCT vs CC+R and the impact of salvage ASCT in patients who received upfront CC+R, we conducted a pooled analysis of 2 phase III trials (RV-MM-209 and EMN-441). Primary endpoints were PFS1, progression-free survival 2 (PFS2), overall survival (OS). A total of 268 patients were randomized to 2 courses of melphalan 200 mg/m2 and ASCT (MEL200-ASCT) and 261 to CC+R. Median follow-up was 46 months. MEL200-ASCT significantly improved PFS1 (median: 42 vs 24 months, HR 0.53; P<0.001), PFS2 (4 years: 71 vs 54%, HR 0.53, P<0.001) and OS (4 years: 84 vs 70%, HR 0.51, P<0.001) compared with CC+R. The advantage was noticed in good and bad prognosis patients. Only 53% of patients relapsing from CC+R received ASCT at first relapse. Upfront ASCT significantly reduced the risk of death (HR 0.51; P=0.007) in comparison with salvage ASCT. In conclusion, these data confirm the role of upfront ASCT as the standard approach for all young myeloma patients.
引用
- Gay F, Oliva S, Petrucci MT, et al. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. Leukemia. 2016. PMID: 28008174. doi:10.1038/leu.2016.381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。